Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC8095 | G-5555 |
| High affinity group 1 PAK (pan-PAK1, 2 and 3) inhibitor (Ki = 3.7 nM; pMEK IC50 = 69 nM). Of 235 kinases tested, other than PAK1, eight (PAK2, PAK3, KHS1, Lck, MST3, MST4, SIK2, and YSK1) were inhibited >70%. Exhibits low hERG channel activity (<50% inhibition at 10 μM). Orally bioavailable. | |
| BCC8096 | Cinaciguat hydrochloride |
| Potent soluble guanylyl cyclase (sGC) activator (EC50 = 6.4 nM). Binds heme-free sGC. Exhibits antihypertensive effects in vivo. | |
| BCN8322 | Chelerythrine chloride |
| Cell-permeable inhibitor of protein kinase C (IC50 = 660 nM); competitive with respect to the phosphate acceptor and non-competitive with respect to ATP. Has a wide range of biological activities, including antiplatelet, anti-inflammatory, antibacterial and antitumor effects. Activates MAPK pathways, independent of PKC inhibition. Inhibits binding of BclXL to Bak (IC50 = 1.5 μM) or Bad proteins and stimulates apoptosis. | |
| BCN8453 | S-(-)-Carbidopa |
| Peripheral decarboxylase inhibitor, used in combination with levodopa for treatment of Parkinsonism. | |
| BCC8817 | Amlexanox |
| Selective inhibitor of TANK-binding kinase 1 (TBK1) and IKKε (IC50 values are ~1-2 μM). Displays no effect on IKKα or IKKβ at these concentrations. Reversibly lowers weight, increases insulin sensitivity, and reduces inflammation and steatosis in three mouse models of obesity. Exhibits antiallergic activity; inhibits the release of histamine from rat mast cells. Also binds to Hsp90 and inhibits C-terminal chaperone activity in vitro. | |
| BCC8839 | Baclofen |
| Selective GABAB receptor agonist. Skeletal muscle relaxant. | |
| BCC8900 | Candesartan cilexetil |
| Prodrug of the angiotensin II receptor 1 (AT1) antagonist candesartan (Cat. No. 4791), which exhibits antihypertensive effects in animal models. | |
| BCC8947 | Diphenhydramine hydrochloride |
| H1 receptor antagonist. Antihistamine. | |
